Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester

Abstract

ABSTRACT. Our aim is to investigate visfatin concentration and its relationship to glycated hemoglobin (HbA 1c ), insulin resistance, lipid parameters, and neonatal birth weight in women with gestational diabetes mellitus (GDM). In our study group, there were 47 women with GDM and 31 women with normal glucose tolerance (NGT) between 33-39 weeks of gestation. Plasma visfatin levels were significantly decreased in pregnant women with GDM compared to those with NGT (p=0.001). Homeostasis model assessmentinsulin resistance (HOMA-IR) levels were higher in the GDM group than in the NGT group (p=0.006). In all subjects, plasma visfatin levels were negatively correlated with HOMA-IR, post-prandial blood glucose, triglycerides, and VLDL cholesterol (p<0.05). We did not observe any statistically significant correlation between the plasma visfatin levels and the selected parameters in the GDM group, but in the NGT group plasma visfatin levels were negatively correlated with HOMA-IR (r=-0.36, p=0.04). There was no correlation between visfatin concentrations and fetal birth weight in either group (p>0.05). By regression analysis, having GDM was found to be the only significant determinant (t=3.5, p=0.001) of visfatin concentration (R=0.39, r 2 =0.15). We conclude that women with GDM have significantly decreased visfatin concentrations in the third trimester. Future studies are required to establish the exact role of visfatin in the pathogenesis of GDM. (J. Endocrinol. Invest. 31: 610-613, 2008)

Are adipokines associated with gestational diabetes mellitus?

“…Current evidence regarding the association of visfatin concentration with GDM is contradictory. Some studies demonstrated increased serum levels of visfatin in women with GDM (11,32,33), while others reported that visfatin concentrations were significantly lower in women with GDM (34,35). Contrary to our study, Lewandowski et al (32) and Akturk et al (35) reported a significant correlation between visfatin and HOMA.…”

Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice

“…Elevated plasma visfatin levels have been reported in patients with type 2 diabetes mellitus [27][28][29][30]. On the other hand, other investigative results showed decreased plasma visfatin levels in patients with type 1 diabetes, liver cirrhosis, exercise in type 2 diabetes, and in the 3 rd trimester of gestational diabetes [31][32][33][34][35]. Elevated visfatin levels were found in hemodialysis patients [36] and a positive correlation of visfatin levels with all stages of chronic kidney disease was observed [37].…”

227: Evidence for differential regulation of the adipokine visfatin in the maternal and fetal compartments in normal spontaneous labor at term

“…Normal pregnancy is associated with alterations in maternal circulating visfatin concentrations [24,31,50,65,70,99]. In addition, gestational diabetes mellitus [5,11,37,42,66], preeclampsia [4,17,24,107], large-for-gestational-age neonate [66], fetal growth restriction [16,47] and preterm labor [53] were linked to changes in circulating maternal visfatin concentrations when compared to normal pregnant women. Consistent with these findings, patients with intraamniotic infection/inflammation have a higher amniotic fluid concentration of visfatin than those without intra-amniotic infection/inflammation [63].…”